Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval
By Ben Glickman
Shares of Invivyd eased in after-hours trading Friday, pulling back from regular-session gains on news of emergency approval for its monoclonal antibody treatment.
Shares were down 2.8% to $4.24 in after-hours trading, following a 41% rise at Friday's close. The stock has risen 12% in the last three months.
Invivyd said Friday that the Food and Drug Administration had given emergency-use permission to Pemgarda for preventing Covid-19 in immunocompromised adolescents and adults.
The treatment is administered as an intravenous infusion and is indicated for people 12 and older weighing at least 40 kilograms, or about 88 pounds.
Chief Executive David Hering said the company expected to have product available in the U.S. imminently.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 22, 2024 18:46 ET (22:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing